MyOwnSkin refers to a specialized form of autologous keratinocyte or skin cell grafting used to treat large areas of burns or complex wounds. The therapy involves harvesting a patient’s own skin cells, expanding them in a laboratory, and reapplying them to the prepared wound bed to encourage durable coverage. This profile explains how the procedure works, who may be candidates, typical outcomes, recovery considerations, and verifiable details drawn from clinical summaries and regulatory filings. The goal is to clarify long-term expectations, limitations, and practical steps for people evaluating this option.
How MyOwnSkin works
The process begins with a small biopsy or harvest of healthy skin from a donor site on the patient’s body. In a controlled setting, cells are isolated and multiplied to produce a thin, manufactured layer suitable for grafting. The wound area is carefully prepared, and the cultured cells are applied and secured with a biological or synthetic dressing. Over days to weeks, the graft integrates, forming a protective barrier that supports healing and reduces infection risk. This approach is typically considered when standard autografts are not sufficient due to the size or nature of the wound.
Cell source and processing
Physicians obtain a minimal amount of healthy skin, isolate keratinocytes and other necessary cells, then expand them on a substrate. The expansion phase can take several days, depending on the required coverage area. Once sufficient cell volume is achieved, the product is transported to the operative suite and applied by a specialized surgical team. Strict aseptic technique and quality controls are used to minimize contamination and variability, which helps preserve graft viability.
Wound preparation and application
For best integration, the wound bed must be healthy, with adequate vascularization and minimal infection. The care team debrides nonviable tissue, manages drainage, and may use specialized meshes or films to support the cell layer. After placement, clinicians monitor the site for adherence, color, and signs of rejection or infection. Dressings are adjusted as needed to protect the graft during the initial phase of incorporation, which is critical for durable coverage.
Eligibility and patient selection
Not every patient with a large wound or burn is automatically a candidate for MyOwnSkin-style therapies. Physicians typically evaluate overall health, nutritional status, comorbidities, and the characteristics of the wound. Candidates often have burns or injuries too extensive for standard split-thickness grafts, or they have experienced graft failure with other treatments. A multidisciplinary team, including surgeons, wound care specialists, and rehabilitation professionals, reviews each case to determine suitability and to optimize conditions before cell application.
Factors influencing candidacy
- Extent and depth of burn or wound
- Availability of suitable donor skin
- Cardiopulmonary and metabolic stability
- Absence of active infection at the recipient site
- Realistic expectations and ability to attend follow-up
Clinical outcomes and effectiveness
Evidence suggests that cultured epithelial autografts can achieve wound coverage, reduce hospital stays, and lower infection rates in selected patients with large burns or complex wounds. Success depends on cell viability, adherence to postoperative protocols, and ongoing management of the healing environment. While outcomes vary, many individuals experience improved healing times and better functional recovery compared with delayed or absent coverage. Long-term durability is often favorable when integrated into a comprehensive burn or wound care program.
Reported outcomes in comparable autologous cell therapies
| Metric | Estimate or Range | Context |
|---|---|---|
| Wound closure time | 2–6 weeks post-application | Time to epithelialization in favorable cases |
| Hospital stay reduction | Up to several weeks versus delayed care | Compared with conservative management in some studies |
| Complication rate | Low to moderate | Infection, partial loss, or revisions may occur |
| Long-term durability | Favorable with proper aftercare | Functional coverage maintained with routine care |
Recovery and aftercare
Recovery following MyOwnSkin application involves close monitoring, pain control, and protection of the grafted area. Patients may need specialized dressings, offloading strategies, and gradual mobilization to support integration. Physical therapy or occupational therapy can help preserve mobility and function, especially when burns involve joints or critical areas. Adherence to follow-up visits allows clinicians to detect early issues, adjust dressings, and reinforce hygiene and skin care practices at home.
Key aftercare steps
- Keep grafts clean and protected per medical instructions
- Attend all scheduled follow-up and dressing-change visits
- Manage nutrition, hydration, and comorbidities actively
- Engage in prescribed rehabilitation to maintain range of motion
- Report redness, increased pain, or discharge promptly
Costs, insurance, and access
Costs for autologous cell-based therapies can be substantial due to laboratory processing, specialized staff, and postoperative care. Insurance coverage varies by plan and region, with some policies covering the procedure when medically necessary and documentation supports medical necessity. Patients are encouraged to work with their care team and insurer early to understand out-of-pocket responsibilities, prior authorization requirements, and available financial assistance. Facility and physician experience, as well as regulatory approvals, may also influence access and pricing.
Risks and limitations
While autologous grafts lower the risk of rejection seen in allografts, they are not without potential complications. These may include infection at the donor or recipient site, partial or complete graft loss, delayed healing, and the need for additional procedures. Underlying medical conditions, such as diabetes or immunosuppression, can further affect recovery. Realistic expectations and careful patient selection are essential to align goals with likely benefits and risks.
Next steps for evaluation
Individuals considering MyOwnSkin or similar cell-based therapies should begin with a comprehensive assessment by a specialized burn or wound care team. Gathering detailed clinical summaries, understanding facility credentials, and clarifying costs and expected timelines can support informed decisions. Ongoing communication with providers ensures that follow-up plans, rehabilitation, and long-term monitoring are in place to optimize outcomes and quality of life.